1122P - Influence of sentinel lymph node biopsy on disease-free survival for melanoma patients

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Melanoma and other Skin Tumours
Surgery and/or Radiotherapy of Cancer
Presenter Mariia Kukushkina
Citation Annals of Oncology (2014) 25 (suppl_4): iv374-iv393. 10.1093/annonc/mdu344
Authors M. Kukushkina1, S. Korovin1, O. Solodiannikova2, G. Sukach2, A. Palivets1, A. Diedkov3, V. Ostafiichuk1
  • 1Skin And Soft Tissue Tumours, National Cancer Institute, 03022 - Kiev/UA
  • 2Radiation Oncolgy, National Cancer Institute, 03022 - Kiev/UA
  • 3Orthopedic Oncology, National cancer institute, 03022 - Kiev/UA



Currently sentinel lymph node biopsy (SLNB) is a standart diagnostic procedure for melanoma patients. Its prognostic significance is undoubtedly. However, the question about therapeutic value of SLNB remains open. The aim of our study is to evaluate the influence of SLNB (without following complete lymph node dissection (CLND) independ on SLN status) on the outcome of patients with skin melanoma.


During 2009-2011 357 patients with primary melanoma were treated. 155 patients underwent wide excision (WE) of skin tumor and SLNB; 202 patients underwent WE of primary tumor. CLND was performed only when lymph node metastasis became clinically detected in the both groups.


In the group with WE and SLNB micrometastasis in SLN were detected in 34/155 patients (21.9%). After a median follow-up of 34.5 months, the 3-year disease-free survival rate did not differ significantly between patients with WE and SLNB and patients with WE (82.6% vs 74.1%, respectively; P = 0.08). At the same time 3-year disease-free survival rate is significantly higher for patients who underwent WE and SLNB compared with those who underwent only WE with thick tumours (68.2% vs 43.3%%, respectively; P = 0.026) and ulceration of primary tumours (91.0% vs 77.5%, respectively; P = 0.048).


Although no significant difference in disease-free survival rate WE and SLNB is associated with a significantly better outcome compared with WE particulary for patients with thick and ulcerated melanoma.


All authors have declared no conflicts of interest.